FDA Backs Telaprevir for Having High Hepatitis C Cure Rate

[Guest guest]

FDA Backs Telaprevir for Having High Hepatitis C Cure Rate

Just a day after doling out similar praise for a comparable drug from Merck, an FDA panel backed the approval of Vertex's telaprevir, largely due to their computation that this drug's Hepatitis C cure rate goes far beyond the current therapy's ability.

Vertex's hepatitis C drug aces review

Telaprevir cures more people more quickly than current options

April 27, 2011 | By Weisman, Globe Staff

A drug developed by Vertex Pharmaceuticals Inc. cures more patients with the hepatitis C virus in less time than existing therapies, according to a briefing document filed yesterday by Food and Drug Administration staffers who reviewed the company's application for approval.

Continue reading this entire article:http://articles.boston.com/2011-04-27/business/29479613_1_fda-advisory-committee-vertex-pharmaceuticals-new-drug

http://www.hepatitis-central.com/mt/archives/2011/05/fda_backs_telap.html